| dc.contributor.author | Ozdemir, Merve | |
| dc.contributor.author | Mumusoglu, Sezcan | |
| dc.contributor.author | Bilgic, Pelin | |
| dc.date.accessioned | 2025-12-28T16:39:58Z | |
| dc.date.available | 2025-12-28T16:39:58Z | |
| dc.date.issued | 2025 | |
| dc.identifier.issn | 1933-7191 | |
| dc.identifier.issn | 1933-7205 | |
| dc.identifier.uri | https://doi.org/10.1007/s43032-025-01808-8 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12933/2270 | |
| dc.description.abstract | This study aims to investigate the effects of a low-advanced glycation end products(AGEs) diet versus a standard AGE-containing weight-loss diet on metabolic and hormonal profiles of overweight phenotype-A polycystic ovary syndrome(PCOS) patients.A randomized controlled interventional study.A total of 44 Rotterdam phenotype-A PCOS patients aged 19-35 were enrolled between January 2022 and May 2023. They were randomly assigned to 12-weeks of an energy-restricted Standard-AGEs diet(S-AGEs) or an energy-restricted Low-AGEs diet(L-AGEs). At baseline and after 12-weeks of intervention, weight loss, oligo-amenorrhea, hormonal profiles, plasma lipid profiles, and inflammation markers were evaluated. During the intervention, 8 participants from the L-AGEs group and 6 from the S-AGEs group dropped out. Completers had similar baseline characteristics to dropouts. In the per-protocol analysis, similar weight loss was observed in the L-AGEs(n = 14) and S-AGEs(n = 16) groups compared to baseline weight [-8.4 [-10.3 to -5.8] vs. -5.2 [-8.8 to -4.6] kg, respectively, p = 0.183]. However, in the L-AGEs group, fasting glucose levels decreased significantly more compared to the S-AGEs group (-8.5 [-11.5 to -3.5] vs. -0.5 [-3.7 to 0.7] mmol/L, respectively, p = 0.027). Following the diet intervention in the L-AGEs group, the waist-to-hip circumference ratio, LDL-cholesterol, TNF-alpha, total testosterone (TT), free-androgen index (FAI), and anti-M & uuml;llerian hormone (AMH) levels significantly decreased compared to baseline levels, while sex hormone-binding globulin (SHBG) levels increased. In contrast, there was no statistically significant change in these parameters in the S-AGEs group.In addition to weight-loss, reducing dietary AGEs intake resulted in significantly greater improvements in metabolic and hormonal profiles among phenotype-A PCOS patients. Clinicaltrials.gov registration no. NCT05830487. | |
| dc.description.sponsorship | Ulusal Metroloji Enstits, Trkiye Bilimsel ve Teknolojik Arascedil;tirma Kurumu | |
| dc.description.sponsorship | The authors want to express their gratitude to the patients participating the trial. | |
| dc.language.iso | en | |
| dc.publisher | Springer Heidelberg | |
| dc.relation.ispartof | Reproductive Sciences | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Advanced glycation end products | |
| dc.subject | Diet | |
| dc.subject | Polycystic ovary syndrome | |
| dc.subject | Phenotype-A | |
| dc.subject | Weight loss | |
| dc.title | Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial | |
| dc.type | Article | |
| dc.identifier.orcid | 0000-0001-7000-7580 | |
| dc.identifier.orcid | 0000-0001-7955-9154 | |
| dc.department | Afyonkarahisar Sağlık Bilimleri Üniversitesi | |
| dc.identifier.doi | 10.1007/s43032-025-01808-8 | |
| dc.identifier.volume | 32 | |
| dc.identifier.issue | 4 | |
| dc.identifier.startpage | 1190 | |
| dc.identifier.endpage | 1201 | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.department-temp | [Ozdemir, Merve] Afyonkarahisar Hlth Sci Univ, Fac Hlth Sci, Dept Nutr & Dietet, Afyon, Turkiye; [Mumusoglu, Sezcan] Hacettepe Univ, Sch Med, Dept Obstet & Gynecol, Ankara, Turkiye; [Bilgic, Pelin] Hacettepe Univ, Fac Hlth Sci, Dept Nutr & Dietet, Ankara, Turkiye | |
| dc.identifier.pmid | 39953370 | |
| dc.identifier.scopus | 2-s2.0-85218813441 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.wos | WOS:001420948700001 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.snmz | KA_WoS_20251227 | |